AD Pipeline Watch: CAGE Bio’s Topical CGB-500 Helps Patients Ditch Itch Early
CAGE Bio’s investigational atopic dermatitis (AD) drug CGB-500 outperformed efficacy benchmarks while meeting safety endpoints, according to topline results a Phase 2b dose-ranging tria. CGB-500 is a novel ionic liquid–based topical therapy for patients with AD. The Phase 2b study enrolled 180 patients ≥12 years of age at 16 sites across the United States. A […]